. "Profily n\u00EDzkomolekul\u00E1rn\u00EDho proteomov\u00E9ho spektra z\u00EDskan\u00E9 pomoc\u00ED hmotnostn\u00ED spektrometrie SELDI-TOF v s\u00E9rech pacient\u016F s diseminovan\u00FDm malign\u00EDm melanomem: pilotn\u00ED studie"@cs . . "Lakom\u00FD, Radek" . "22" . "Piln\u00FD, Radom\u00EDr" . "RIV/00209805:_____/09:#0000102" . "Profily n\u00EDzkomolekul\u00E1rn\u00EDho proteomov\u00E9ho spektra z\u00EDskan\u00E9 pomoc\u00ED hmotnostn\u00ED spektrometrie SELDI-TOF v s\u00E9rech pacient\u016F s diseminovan\u00FDm malign\u00EDm melanomem: pilotn\u00ED studie"@cs . "7"^^ . . . . . "Pomoc\u00ED surface-enhanced laser desorption/ ionisation time of flight mass spectrometry (SELDI-TOF-MS) jsme provedli pilotn\u00ED anal\u00FDzu proteinov\u00E9ho spektra u 25 pacient\u016F s diseminovan\u00FDm malign\u00EDm melanonem, l\u00E9\u010Den\u00FDch paliativn\u00ED syst\u00E9movou chemoterapi\u00ED na na\u0161em pracovi\u0161ti v letech 2004\u2013 2006. Soubor byl rozd\u011Blen na dv\u011B skupiny: skupina s n\u00E1dory rezistentn\u00EDmi k chemoterapii \u2013 14 pacient\u016F \u2013 a skupina, kter\u00E1 m\u011Bla ur\u010Dit\u00FD klinick\u00FD benefit z podan\u00E9 l\u00E9\u010Dby (kompletn\u00ED a parci\u00E1ln\u00ED remise, stabilizace onemocn\u011Bn\u00ED) \u2013 11 pacient\u016F. C\u00EDlem experimentu bylo objevit proteinov\u00E9 profily charakteristick\u00E9 pro tyto skupiny a d\u00E1le na z\u00E1klad\u011B v\u0161ech proteinov\u00FDch profil\u016F bez ohledu na l\u00E9\u010Debnou odpov\u011B\u010F prov\u00E9st rozd\u011Blen\u00ED cel\u00E9ho souboru pacient\u016F do nov\u00FDch podskupin. Z\u00E1v\u011Brem n\u00E1s zaj\u00EDmaly rozd\u00EDly v laboratorn\u00EDch a klinick\u00FDch parametrech, a to jak mezi skupinami chemorezistentn\u00EDch a chemosenzitivn\u00EDch pacient\u016F, tak i mezi nov\u011B vytvo\u0159en\u00FDmi podskupinami s podobn\u00FDmi proteinov\u00FDmi profily." . "[C8E6B88815A5]" . . "P(LC06035), P(NR8338), Z(MZ0MOU2005)" . "8"^^ . . . "Vyzula, Rostislav" . . "Proteomic, biomarkers, SELDI-TOF-MS"@en . . . "N\u011Bme\u010Dek, Radim" . . "CZ - \u010Cesk\u00E1 republika" . "Val\u00EDk, Dalibor" . "Profiles of low-molecular proteome spestrum obtained through SELDI-TOF mass spectrometry in the sera of patients with metastatic malignant melanoma: pilot study"@en . . . . . "0862-495X" . "Profily n\u00EDzkomolekul\u00E1rn\u00EDho proteomov\u00E9ho spektra z\u00EDskan\u00E9 pomoc\u00ED hmotnostn\u00ED spektrometrie SELDI-TOF v s\u00E9rech pacient\u016F s diseminovan\u00FDm malign\u00EDm melanomem: pilotn\u00ED studie" . "Pomoc\u00ED surface-enhanced laser desorption/ ionisation time of flight mass spectrometry (SELDI-TOF-MS) jsme provedli pilotn\u00ED anal\u00FDzu proteinov\u00E9ho spektra u 25 pacient\u016F s diseminovan\u00FDm malign\u00EDm melanonem, l\u00E9\u010Den\u00FDch paliativn\u00ED syst\u00E9movou chemoterapi\u00ED na na\u0161em pracovi\u0161ti v letech 2004\u2013 2006. Soubor byl rozd\u011Blen na dv\u011B skupiny: skupina s n\u00E1dory rezistentn\u00EDmi k chemoterapii \u2013 14 pacient\u016F \u2013 a skupina, kter\u00E1 m\u011Bla ur\u010Dit\u00FD klinick\u00FD benefit z podan\u00E9 l\u00E9\u010Dby (kompletn\u00ED a parci\u00E1ln\u00ED remise, stabilizace onemocn\u011Bn\u00ED) \u2013 11 pacient\u016F. C\u00EDlem experimentu bylo objevit proteinov\u00E9 profily charakteristick\u00E9 pro tyto skupiny a d\u00E1le na z\u00E1klad\u011B v\u0161ech proteinov\u00FDch profil\u016F bez ohledu na l\u00E9\u010Debnou odpov\u011B\u010F prov\u00E9st rozd\u011Blen\u00ED cel\u00E9ho souboru pacient\u016F do nov\u00FDch podskupin. Z\u00E1v\u011Brem n\u00E1s zaj\u00EDmaly rozd\u00EDly v laboratorn\u00EDch a klinick\u00FDch parametrech, a to jak mezi skupinami chemorezistentn\u00EDch a chemosenzitivn\u00EDch pacient\u016F, tak i mezi nov\u011B vytvo\u0159en\u00FDmi podskupinami s podobn\u00FDmi proteinov\u00FDmi profily."@cs . "5"^^ . "Greplov\u00E1, Krist\u00EDna" . "Profily n\u00EDzkomolekul\u00E1rn\u00EDho proteomov\u00E9ho spektra z\u00EDskan\u00E9 pomoc\u00ED hmotnostn\u00ED spektrometrie SELDI-TOF v s\u00E9rech pacient\u016F s diseminovan\u00FDm malign\u00EDm melanomem: pilotn\u00ED studie" . "We analyzed human blood serum samples from 25 patients with metastatic malignant melanoma treated with palliative chemotherapy at the Masaryk Memorial Cancer Institute, Brno, in 2004-2006. The analysis was performed by Surface Enhanced Laser Desorption/lonisation Time of Flight Mass Spectrometry (SELDI-TOF-MS). Our patients were divided into two subgroups: a group relatively resistant to chemotherapy--14 patients--and a group with certain clinical benefit from the treatment (complete and partial remission, stabilized disease)--11 patients. We were searching for a new biomarker or typical protein profile in the selected two subgroups. Then, we recategorized our patients into three groups according to the similarity of their protein profiles regardless of sensitivity to chemotherapy. Finally, we evaluated differences in laboratory and clinical parameters, between both the groups of chemo-resistant and chemo-sensitive patients, and newly defined subgroups with similar protein profiles."@en . . "Profiles of low-molecular proteome spestrum obtained through SELDI-TOF mass spectrometry in the sera of patients with metastatic malignant melanoma: pilot study"@en . "Poprach, Alexandr" . . "RIV/00209805:_____/09:#0000102!RIV10-MZ0-00209805" . . . . "5" . "336850" . . . "Klinick\u00E1 onkologie" .